HZS C2BRNE DIARY – January 2021
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The 49Th Annual Meeting of the Japanese Society for Immunology
http://icongroup.co.jp/49immunology/ The 49th Annual Meeting of the Japanese Society for Immunology December 8, 2020-Online Meeting P r e s i d e n t: Hiroshi Kiyono, President and Chairman of Board, JSI COVID-19 and Immunity Keynote Remarks Registration Anthony S. Fauci, Director of NIAID, U.S.A. http://icongroup.co.jp/49immunology/ November 2 (Noon - JST) Symposium Early -November 30 (Noon - JST) Vaccine and Immunity * Credit card or Bank transfer December 1 (Noon - JST) Akiko Iwasaki, Yale University, U.S.A. Late -December 25 (Noon - JST) Alessandro Sette, La Jolla Institute for Immunology, U.S.A. * Credit card only George Fu Gao, China CDC, China Regular Member: 1,000JPY, Student Member: Free Hironori Nakagami, Osaka University, Japan Non-member: 2,000JPY, Student Non-member: 500JPY Ken J Ishii, The University Tokyo, Japan Cytokine Storm and Related Disease ■Steering committee & Program Committee Tadamitsu Kishimoto, Osaka University, Japan Chair: Toshiaki Ohteki, Tokyo Medical and Dental University Josef Penninger, University of British Columbia, Canada Members: Miyuki Azuma, Tokyo Medical and Dental University Yumiko Imai, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Japan Tsuneyasu Kaisho, Wakayama Medical University Takanori Kanai, Keio University, Japan Hiroshi Kawamoto, Kyoto University Hisashi Arase, Osaka University, Japan Noriko Sorimachi, National Center for Global Health and Medicine Kiyoshi Takeda, Osaka University Shohei Hori, The University of Tokyo Review Talk (in Japanese) Koji Yasutomo, -
Cov-2 Wastewater Surveillance System (Vatar COVID-19) from December 2020 to March
medRxiv preprint doi: https://doi.org/10.1101/2021.05.27.21257918; this version posted May 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Monitoring emergence of SARS-CoV-2 B.1.1.7 Variant through the Spanish National SARS- CoV-2 Wastewater Surveillance System (VATar COVID-19) from December 2020 to March 2021 Albert Carcereny1, Adán Martínez-Velázquez1, Albert Bosch1, Ana Allende2, Pilar Truchado2, Jenifer Cascales2, Jesús L Romalde3, Marta Lois3, David Polo3, Gloria Sánchez4, Alba Pérez- Cataluña4, Azahara Díaz-Reolid4, Andrés Antón5, Josep Gregori6,7, Damir Garcia-Cehic6,7, Josep Quer6,7, Margarita Palau8, Cristina González Ruano9, Rosa M Pintó1#* and Susana Guix1#* 1 Enteric Virus laboratory, Department of Genetics, Microbiology and Statistics, Section of Microbiology, Virology and Biotechnology, School of Biology, and Institute of Nutrition and Food Safety (INSA), University of Barcelona, Barcelona, Spain. 2 Research Group on Microbiology and Quality of Fruit and Vegetables, CEBAS-CSIC, Campus Universitario de Espinardo, 25, 30100, Murcia, Spain. 3 Department of Microbiology and Parasitology, CIBUS-Faculty of Biology & Institute CRETUS, Universidade de Santiago de Compostela, Santiago de Compostela, 15782, Spain. 4 Department of Preservation and Food Safety Technologies, Institute of Agrochemistry and Food Technology, IATA-CSIC, Av. Agustín Escardino 7, Paterna, 46980, Valencia, Spain. 5 Microbiology Department, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain. -
July 2020 Strategies for Emerging Infectious Diseases
THE AMERICAN WWW.CAYMANCHEM.COM ASSOCIATION OF IMMUNOLOGISTS AT ISSUE NEW THE DOWNLOAD Virus Life Cycle Infographic Infographic Cycle Life Virus JULY 2020 Resources for Your Research Your for Resources Informative Articles Informative CAYMAN CURRENTS: CAYMAN IN THIS ISSUE OF THE THE OF ISSUE THIS IN DISEASES INFECTIOUS EMERGING AAI Looks Back: How Honolulu’s Chinatown FOR STRATEGIES "Went Up in Smoke" A history of the first plague outbreak in Hawai’i, page 30 ANTIVIRAL 28 No. Permit CAYMAN CURRENTS PA Gettysburg, PAID 20852 20852 20852 20852 MD MD MD MD Rockville, Rockville, Rockville, Rockville, 650, 650, 650, 650, Suite Suite Suite Suite Pike, Pike, Pike, Pike, Rockville Rockville Rockville Rockville 1451 1451 1451 1451 Postage U.S. Non-Proft Org. Non-Proft IMMUNOLOGISTS IMMUNOLOGISTS IMMUNOLOGISTS IMMUNOLOGISTS OF OF OF OF ASSOCIATION ASSOCIATION ASSOCIATION ASSOCIATION AMERICAN AMERICAN AMERICAN AMERICAN THE THE THE THE 2020 advanced Course in Immunology Now Virtual! I July 26–31, 2020 IN THIS ISSUE Director: Wayne M. Yokoyama, M.D. Washington University School of Medicine in St. Louis x4 Executive Offce The American Association Don’t miss the premier course in immunology for research scientists! of Immunologists x8 Public Affairs This intensive course is directed toward advanced trainees and scientists who wish to expand or update 1451 Rockville Pike, Suite 650 their understanding of the feld. Leading experts will present recent advances in the biology of the Rockville, MD 20852 20 Members in the News immune system and address its role in health and disease. This is not an introductory course; Tel: 301-634-7178 attendees will need to have a frm understanding of the principles of immunology. -
Lest We Forget the Horrors: a Catalog of Trump’S Worst Cruelties, Collusions, Corruptions, and Crimes
COPYRIGHT MCSWEENEY’S 2020/2021 MCSWEENEYS.NET LEST WE FORGET THE HORRORS: A CATALOG OF TRUMP’S WORST CRUELTIES, COLLUSIONS, CORRUPTIONS, AND CRIMES THE COMPLETE LISTIN G : ATROCITIES 1- 1056 BY BEN PARKER, STEPHANIE STEINBRECHER, KELSEY RONAN, JOHN M C MURTRIE, SOPHIA D U ROSE, RACHEL VILLA, AND AMY SUMERTON - - - Early in President Trump’s term, McSweeney’s editors began to catalog the head-spinning number of misdeeds coming from his administration. We called this list a collection of Trump’s cruelties, collusions, and crimes, and it felt urgent then to track them, to ensure these horrors — happening almost daily — would not be forgotten. This election year, amid a harrowing global health, civil rights, humanitarian, and economic crisis, we know it’s never been more critical to note these horrors, to remember them, and to do all in our power to reverse them. - - - Various writers have compiled this list during the course of the Trump administration. Their work has been guided by invaluable journalistic resources, including WTFJHT, NPR, the New York Times, the Washington Post, and other sources, to whom we are grateful. - - - ATROCITY KEY – Sexual Misconduct, Harassment, & Bullying – White Supremacy, Racism, Homophobia, Transphobia, & Xenophobia – Public Statements / Tweets – Collusion with Russia & Obstruction of Justice – Trump Staff & Administration – Trump Family Business Dealings – Policy – Environment - - - BEFORE JANUARY 2017 1. – February 10, 2011 – In 2011, Donald Trump stoked false claims that Barack Obama had lied about his education. During a speech to the Conservative Political Action Conference, Trump said, “Our current president came out of nowhere. Came out of nowhere. In fact, I’ll go a step further: The people that went to school with him, they never saw him, they don’t know who he is. -
An Interview with Akiko Iwasaki on Her Groundbreaking COVID Projects and Advocacy for Women and Minorities in STEM
Q&A https://doi.org/10.1038/s42003-021-02456-9 OPEN At the frontline of COVID research: an interview with Akiko Iwasaki on her groundbreaking COVID projects and advocacy for women and minorities in STEM Professor Akiko Iwasaki’s research focuses on the mechanisms of immune defense against viruses at mucosal surfaces, which are a major site of entry for infectious agents. Professor Iwasaki received her Ph.D. in Immunology from the University of Toronto and completed her postdoctoral training with the National Institutes of Health before joining Yale’s faculty in 2000. She has received many awards and honors and has been a Howard Hughes Medical Institute Investigator since 2014. She was elected to the 1234567890():,; National Academy of Sciences in 2018, to the National Academy of Medicine in 2019 and to the American Academy of Arts and Sciences in 2021. Professor Iwasaki is also well known for her Twitter advocacy of women and underrepresented minorities in the science and medicine fields. In addition, Professor Iwasaki co-directs the IMPACT (Implementing Medical and Public Health Actions against Coronavirus in Connecticut) team to generate an extensive biorepository for specimens collected from patients and health care workers, as well as implementing viral testing in both groups. established. Based on this insight, we developed a vaccine strategy called “Prime and Pull”, where we can recruit and establish tissue resident memory T cells at the site of viral encounter. This led to a much more robust protection from genital herpes, and can also be used to treat existing virus infection to prevent recurrence of herpes lesions. -
SARS-Cov-2 Protein Subunit Vaccination Elicits Potent Neutralizing Antibody Responses
bioRxiv preprint doi: https://doi.org/10.1101/2020.07.31.228486; this version posted July 31, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses Marco Mandolesi1,*, Daniel J. Sheward1,2,*, , Leo Hanke1, Junjie Ma1, Pradeepa Pushparaj1, Laura Perez Vidakovics1, Changil Kim1, Karin Loré3, Xaquin Castro Dopico1, Jonathan M. Coquet1, Gerald McInerney1, Gunilla B. Karlsson Hedestam1,†, , and Ben Murrell1,†, 1Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden 2Division of Medical Virology, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, South Africa 3Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden *These authors contributed equally †These authors contributed equally The outbreak and spread of SARS-CoV-2 (Severe Acute Res- Results piratory Syndrome coronavirus 2), the cause of coronavirus dis- ease 2019 (COVID-19), is a current global health emergency and To evaluate the use and immunogenicity of recombinant a prophylactic vaccine is needed urgently. The spike glycopro- protein subunit vaccines for SARS-CoV-2 we immunized tein of SARS-CoV-2 mediates entry into host cells, and thus is a C57BL/6J mice (N=24) with either the spike ectodomain or target for neutralizing antibodies and vaccine design. Here we RBD, expressed in 293-F cells. The RBD domain was ex- show that adjuvanted protein immunization with SARS-CoV-2 pressed as an Fc-fusion protein, which was cleaved and the 1 spike trimers, stabilized in prefusion conformation , results in RBD subsequently purified by size-exclusion chromatogra- potent antibody responses in mice and rhesus macaques with phy. -
Download PDF (2.6
A Proposal to End the COVID-19 Pandemic Prepared by Ruchir Agarwal and Gita Gopinath* Authorized for distribution by Gita Gopinath DISCLAIMER: Staff Discussion Notes (SDNs) showcase policy-related analysis and research being developed by IMF staff members and are published to elicit comments and to encourage debate. The views expressed in Staff Discussion Notes are those of the author(s) and do not necessarily represent the views of the IMF, its Executive Board, or IMF management. Urgent steps are needed to arrest the rising human toll and economic strain from the COVID-19 pandemic that are exacerbating already-diverging recoveries. Pandemic policy is also economic policy as there is no durable end to the economic crisis without an end to the health crisis. Building on existing initiatives, this paper proposes pragmatic actions at the national and multilateral level to expeditiously defeat the pandemic. The proposal targets: (1) vaccinating at least 40 percent of the population in all countries by the end of 2021 and at least 60 percent by the first half of 2022, (2) tracking and insuring against downside risks, and (3) ensuring widespread testing and tracing, maintaining adequate stocks of therapeutics, and enforcing public health measures in places where vaccine coverage is low. The benefits of such measures at about $9 trillion far outweigh the costs which are estimated to be around $50 billion—of which $35 billion should be paid by grants from donors and the residual by national governments potentially with the support of concessional financing from bilateral and multilateral agencies. The grant funding gap identified by the Access to COVID-19 Tools (ACT) Accelerator amounts to about $22 billion, which the G20 recognizes as important to address. -
Page 1 May 2021 SD N /2021/4
May 2021 I M F S T A F F D I S C U S S I O N N O T E A Proposal to End the COVID-19 Pandemic SDN/2021/4 Ruchir Agarwal, Gita Gopinath DISCLAIMER: Staff Discussion Notes (SDNs) showcase policy-related analysis and research being developed by IMF staff members and are published to elicit comments and to encourage debate. The views expressed in Staff Discussion Notes are those of the author(s) and do not necessarily represent the views of the IMF, its Executive Board, or IMF management. A Proposal to End the COVID-19 Pandemic Prepared by Ruchir Agarwal and Gita Gopinath* Authorized for distribution by Gita Gopinath DISCLAIMER: Staff Discussion Notes (SDNs) showcase policy-related analysis and research being developed by IMF staff members and are published to elicit comments and to encourage debate. The views expressed in Staff Discussion Notes are those of the author(s) and do not necessarily represent the views of the IMF, its Executive Board, or IMF management. Urgent steps are needed to arrest the rising human toll and economic strain from the COVID-19 pandemic that are exacerbating already-diverging recoveries. Pandemic policy is also economic policy as there is no durable end to the economic crisis without an end to the health crisis. Building on existing initiatives, this paper proposes pragmatic actions at the national and multilateral level to expeditiously defeat the pandemic. The proposal targets: (1) vaccinating at least 40 percent of the population in all countries by the end of 2021 and at least 60 percent by the first half of 2022, (2) tracking and insuring against downside risks, and (3) ensuring widespread testing and tracing, maintaining adequate stocks of therapeutics, and enforcing public health measures in places where vaccine coverage is low. -
Tuberculosis Diagnostic Research: Beyond the Basics December 13 - 15, 2010, Tuberculosis Research Centre, Chennai, India
Tuberculosis Diagnostic Research: Beyond the Basics December 13 - 15, 2010, Tuberculosis Research Centre, Chennai, India COURSE SCHEDULE Monday, Dec 13, 2010 Time Lecture Faculty 8.30 AM Welcome and Introductions A Thomas, MS Jawahar, all 9.00 AM The global value chain (blueprint) for TB diagnostics and current M Pai pipeline of diagnostics 9.45 AM New WHO policy on Xpert MTB/RIF CN Paramasivan New WHO policy on serological assays K Steingart 10.30 AM Coffee 10.45 AM Overview of diagnostic research and types of diagnostic study M Pai designs 11.15 AM Landscape of TB diagnostic research M Pai 12.30 PM Lunch 1.30 PM The diagnostic test accuracy design M Pai 2.30 PM Bias in diagnostic research and sources of variation K Steingart 3.30 PM Coffee 4.00 - 5.30 PM Optimism bias in TB diagnostic research & critical appraisal M Pai Tuesday, Dec 14, 2010 Time Lecture Faculty 8.30 AM Setting reference standards in TB diagnostic studies: • Microscopy evaluations CN Paramasivan • Rapid culture methods CN Paramasivan • Molecular assays T Shinnick • Serological assays S Laal • IGRAs and LTBI tests M Pai • Extrapulmonary TB J Peter 10.30 AM Coffee 10.45 PM Lab accreditation and QA in India J Kenneth Ensuring quality in diagnostic trials: • Microscopy studies CN Paramasivan CN Paramasivan • Culture studies T Shinnick • Molecular assay studies S Laal • Immunodiagnostic studies 1 12.00 Noon Introduction to TB biomarker validation S Parida 12.30 PM Lunch 1.30 PM Beyond test accuracy - 1: impact of testing on diagnostic M Pai thinking and clinical decision -
Hangar Fire Foam Systems: a Problem in the Aviation Industry, with One Event Occuring on Average Every Six Weeks
PUBLICATIONS Vol.49 | No.7 $9.00 JULY 2020 | ainonline.com USAIG Accidental hangar fire foam discharge is a growing Hangar fire foam systems: a problem in the aviation industry, with one event occuring on average every six weeks. The cleanup solution looking for a problem? costs from each can involve numerous insurance by Curt Epstein claims and in some cases lawsuits, pitting aircraft For FBOs, OEMs, and other hangar keepers, senior v-p of insurance provider Global Aero- could be worth more than 10 times the price owners and operators the inadvertent discharge of fire foam sys- space and the author of a white paper on the of the building. against hangar keepers tems is a persistent and growing problem. topic, stated that the average value of foam dis- As aircraft increased in size and fuel and fire system providers. Nearly everyone has seen photos taken in charge claims he has seen has been $1 million. capacity, fire authorities began to worry the aftermath of one of these events—a NATA estimates the overall clean up and air- that sprinklers would not be able to ade- hangar filled with a thick layer of foam that craft damage costs of those events at between quately reach and fight any fuel spill fires can reach 10 feet high, spilling out on to the $64 million and $235 million. that occurred under the ever-widening ramp in some cases. The National Fire Protection Association wings, which at the time had an unpleasant Electric Aircraft In a way, accidental foam discharge is like (NFPA), considered the world’s foremost tendency to leak fuel onto the hangar floor. -
Standards to Support an Enduring Capability in Wastewater Surveillance for Public Health
DHS/NIST Workshop: Standards to Support an Enduring Capability in Wastewater Surveillance for Public Health Poster Abstracts June 14-18th 2021 Virtual Poster Session https://swwsworkshop.virtualpostersession.org/ CEDAR-MC: Clinical and Environmental Dynamics of Antibiotic Resistance within Microbial Communities George Hanna1,2, Bashir Hamidi1, Scott Curry1, Cheryl Carmack2, Alexander V. Alekseyenko1 1Medical University of South Carolina; 2Charleston Waterkeeper Introduction: Escape into the environment and the persistence of antibiotic resistance is an imminent threat to the healthcare advances attained in the 20th century. Microbial communities that co-exist with resistant bacteria may help uncover novel strategies for global antimicrobial control and curb emergence and maintenance of resistance. However, availability of clinically relevant specimens with complementary samples from the built and natural environment is a major obstacle to effective studies of the dynamics of resistance in the affected human populations and in their surroundings. Methods: We bring together environmental and clinical measurements of the microbial communities with evidence for emerging resistance by linking existing local clinical and environmental surveillance programs. The clinical specimens are sourced from the Medical University of South Carolina (MUSC) infection surveillance culture program that routinely samples the MUSC patient population for clinically relevant pathogens. The environmental specimens are the result of partnership with a local non-profit, -
Recent Zoonotic and Vector-Borne Viral Threats NIAID Vaccine
4/1/2020 PROTOTYPE PATHOGEN APPROACH TO PANDEMIC PREPAREDNESS HIV→PNEUMOVIRUS→PARAMYXOVIRUS→CORONAVIRUS ADVAC Alumni 2 April 2020 Barney S. Graham, MD, PhD Deputy Director Vaccine Research Center, NIAID, NIH 1 Recent Zoonotic and Vector-borne Viral Threats • Hanta virus • Nipah/Hendra • West Nile virus • SARS • Influenza • Chikungunya • Ebola • MERS • Zika • EV‐D68 • SARS‐CoV‐2 2 NIAID Vaccine Research Center Basic Research Process Development Nucleic acid Vectors VLPs • AIDS/HIV • Influenza Proteins and cGMP Manufacturing nanoparticles • Ebola/Marburg • RSV • Malaria Monoclonal antibodies • Tuberculosis • EID GLP Analysis • West Nile virus, Zika • Chikungunya • W/E/V equine encephalitis viruses • MERS‐CoV, SARS, and other CoV • Nipah and other paramyxoviruses • EV‐D68 and other picornaviruses Clinical Trials • Smallpox 3 1 4/1/2020 Public health burden of re-emerging & emerging viruses Traditional Approaches • Licensed vaccines/antibiotics Vaccine • Passive surveillance Challenges • Contact tracing • Quarantine • Vaccines for unmet needs • Emerging viruses • Improving licensed vaccines 4 4 New Technologies are Transforming Vaccinology • Structure-based vaccine design Structural analysis of antigenic sites on viral • Single-cell sorting, sequencing, and bioinformatics surface glycoproteins – Rapid isolation of human mAbs Isolation of human monoclonal – Definition of antibody lineages antibodies from single B cells – Analysis of immune responses • Protein engineering of self-assembling nanoparticles • Rapid DNA synthesis • Recombinant